Mayzent

Siponimod, the active ingredient in Mayzent, is a sphingosine 1‑phosphate (S1P) receptor modulator presented as a oral tablet for oral use. It treats relapsing forms of multiple sclerosis and secondary progressive multiple sclerosis in adult patients. It is approved in the European Union as a disease‑modifying therapy that reduces the frequency of relapses and may slow disability progression. GNH USA supplies Mayzent as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, including North America, Europe and Asia.

Mayzent (siponimod) is used in the management of multiple sclerosis, a chronic autoimmune disease of the central nervous system. - Relapsing forms of multiple sclerosis: reduces relapse frequency and may slow disability accumulation. - Secondary progressive multiple sclerosis with active disease: delays worsening of disability. - Overall disease‑modifying therapy for multiple sclerosis: provides long‑term control of neuroinflammation.

Siponimod may cause a range of adverse reactions, which are categorized by frequency and severity. Common Side Effects: - Headache: mild to moderate headache. - Upper respiratory tract infection: cough, sore throat or nasal congestion. - Elevated liver enzymes: transient increase in ALT/AST. - Hypertension: mild rise in blood pressure. - Diarrhea: loose stools. - Nausea: feeling of sickness. Serious or Rare Side Effects: - Severe infections: opportunistic infections such as herpes zoster, pneumonia, or fungal infections. - Cardiac conduction abnormalities: bradyarrhythmia, heart block, or prolonged QT interval. - Macular edema: swelling of the central retina that may affect vision and require ophthalmologic monitoring.

When prescribing siponimod, clinicians should observe several safety precautions to minimize risks. - Baseline cardiac assessment: perform ECG and monitor heart rate before initiating therapy. - Lymphocyte count monitoring: check absolute lymphocyte count regularly during treatment. - Liver function testing: assess ALT/AST levels prior to start and periodically thereafter. - Infection risk evaluation: screen for active infections and consider prophylaxis for latent tuberculosis. - Vaccination considerations: avoid live vaccines while on treatment. - Store at ambient temperature: keep tablets below 25°C in original packaging, protect from moisture.

Siponimod can interact with other medicines, influencing its efficacy or safety. Major Interactions (Avoid): - CYP3A4 strong inhibitors: co‑administration with ketoconazole, itraconazole, or clarithromycin can markedly increase siponimod exposure. - CYP3A4 strong inducers: agents such as rifampicin or carbamazepine may reduce siponimod levels and diminish therapeutic effect. Moderate Interactions (Monitor Closely): - CYP2C9 inhibitors: fluconazole or amiodarone may modestly raise siponimod concentrations. - Vaccines: live attenuated vaccines may have reduced efficacy; timing should be coordinated. - Antihypertensives: siponimod may potentiate blood‑pressure‑lowering effects, requiring monitoring.